Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan Gauthier

Showing results (51-60 of 87) with videos related to

Pageof 9
Sort By:
Haematologica|July 2, 2026
A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphomaValentín Ortiz-Maldonado, Emily C Liang, Jennifer J Huang, et al.
JCO Clinical Cancer Informatics|January 14, 2026
Time-Series Clustering Captures Patterns of Early Immune Effector Cell-Associated Hematotoxicity That Are Predictable Using Tree-Based ModelsEmily C Liang, Yein Jeon, Yang Qiao, et al.
Blood Advances|September 29, 2023
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLLEmily C Liang, Aya Albittar, Jennifer J Huang, et al.
The Lancet. Haematology|January 22, 2021
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort studyAkshay Sharma, Neel S Bhatt, Andrew St Martin, et al.
Blood|March 9, 2017
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphomaCharles Herbaux, Jordan Gauthier, Pauline Brice, et al.
Blood Advances|October 25, 2019
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapyMazyar Shadman, Jordan Gauthier, Kevin A Hay, et al.
Journal for Immunotherapy of Cancer|November 18, 2025
Novel antibodies for identification, selection, and manipulation of T cells expressing Whitlow linker-containing CARsErik L Kimble, Jocelyn H Wright, Aiko Torkelson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2023
Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell TherapyEleftheria Kampouri, Sarah S Ibrahimi, Hu Xie, et al.
Blood Advances|September 12, 2022
Humoral and cellular responses to SARS-CoV-2 vaccines before and after chimeric antigen receptor-modified T-cell therapyMichael A Gonzalez, Atif M Bhatti, Kristin Fitzpatrick, et al.
Blood|February 21, 2020
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failureJordan Gauthier, Alexandre V Hirayama, Janaki Purushe, et al.
Pageof 9

Showing results (51-60 of 87) with videos related to

Sort By:
Pageof 9
Haematologica|July 2, 2026
A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphomaValentín Ortiz-Maldonado, Emily C Liang, Jennifer J Huang, et al.
JCO Clinical Cancer Informatics|January 14, 2026
Time-Series Clustering Captures Patterns of Early Immune Effector Cell-Associated Hematotoxicity That Are Predictable Using Tree-Based ModelsEmily C Liang, Yein Jeon, Yang Qiao, et al.
Blood Advances|September 29, 2023
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLLEmily C Liang, Aya Albittar, Jennifer J Huang, et al.
The Lancet. Haematology|January 22, 2021
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort studyAkshay Sharma, Neel S Bhatt, Andrew St Martin, et al.
Blood|March 9, 2017
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphomaCharles Herbaux, Jordan Gauthier, Pauline Brice, et al.
Blood Advances|October 25, 2019
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapyMazyar Shadman, Jordan Gauthier, Kevin A Hay, et al.
Journal for Immunotherapy of Cancer|November 18, 2025
Novel antibodies for identification, selection, and manipulation of T cells expressing Whitlow linker-containing CARsErik L Kimble, Jocelyn H Wright, Aiko Torkelson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2023
Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell TherapyEleftheria Kampouri, Sarah S Ibrahimi, Hu Xie, et al.
Blood Advances|September 12, 2022
Humoral and cellular responses to SARS-CoV-2 vaccines before and after chimeric antigen receptor-modified T-cell therapyMichael A Gonzalez, Atif M Bhatti, Kristin Fitzpatrick, et al.
Blood|February 21, 2020
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failureJordan Gauthier, Alexandre V Hirayama, Janaki Purushe, et al.
Pageof 9